Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adriana Petrazzuolo, Maria Perez-Lanzon, Peng Liu, M. Chiara Maiuri, Guido Kroemer
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	alk inhibitors immunogenicity anaplastic large cell lymphoma Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e23c9a7cc4f4489bbcbe3bcb80d2149b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e23c9a7cc4f4489bbcbe3bcb80d2149b
record_format	dspace
spelling	oai:doaj.org-article:e23c9a7cc4f4489bbcbe3bcb80d2149b2021-11-04T15:00:45ZCrizotinib and ceritinib trigger immunogenic cell death via on-target effects2162-402X10.1080/2162402X.2021.1973197https://doaj.org/article/e23c9a7cc4f4489bbcbe3bcb80d2149b2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/2162402X.2021.1973197https://doaj.org/toc/2162-402XImmunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.Adriana PetrazzuoloMaria Perez-LanzonPeng LiuM. Chiara MaiuriGuido KroemerTaylor & Francis Grouparticlealk inhibitorsimmunogenicityanaplastic large cell lymphomaImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoImmunology, Vol 10, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	alk inhibitors immunogenicity anaplastic large cell lymphoma Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	alk inhibitors immunogenicity anaplastic large cell lymphoma Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Adriana Petrazzuolo Maria Perez-Lanzon Peng Liu M. Chiara Maiuri Guido Kroemer Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
description	Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.
format	article
author	Adriana Petrazzuolo Maria Perez-Lanzon Peng Liu M. Chiara Maiuri Guido Kroemer
author_facet	Adriana Petrazzuolo Maria Perez-Lanzon Peng Liu M. Chiara Maiuri Guido Kroemer
author_sort	Adriana Petrazzuolo
title	Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_short	Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_full	Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_fullStr	Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_full_unstemmed	Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_sort	crizotinib and ceritinib trigger immunogenic cell death via on-target effects
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/e23c9a7cc4f4489bbcbe3bcb80d2149b
work_keys_str_mv	AT adrianapetrazzuolo crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects AT mariaperezlanzon crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects AT pengliu crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects AT mchiaramaiuri crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects AT guidokroemer crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects
_version_	1718444804631691264

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

Ejemplares similares